Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06565195 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
A Phase 1 study of Parkinson's Disease, sponsored by Prevail Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
- 4
- Study locations
NCT06565195: Recruiting Phase 1 study of Parkinson's Disease, sponsored by Prevail Therapeutics.
NCT06565195 is a Phase 1 study of Parkinson's Disease that is actively recruiting participants, run by Prevail Therapeutics. The registered enrollment target is 108 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (83% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06565195, a Phase 1 study of Parkinson's Disease, is actively recruiting participants, sponsored by Prevail Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and PK/PD of LY3962681 in healthy volunteers and patients with Parkinson's disease. The study will be comprised of two parts, the Single Ascending Dose (SAD) study and the Multiple Ascending Doses (MAD) study. During the SAD portion of the study, healthy volunteers will receive a single dose of LY3962681 or placebo (artificial cerebrospinal fluid (aCSF), no active drug) given into the spinal fluid. During the MAD portion of the study, patients with Parkinson's disease will receive two doses of either LY3962681 or placebo (aCSF) administered into the spinal fluid. * The treatment period in the SAD study will be 1 day. The treatment period in the MAD study will be 2 days, 12 to 24 weeks apart. * The follow-up period in the SAD study will be up to 52 weeks. The follow-up period in the MAD study will be up to 52 weeks post Dose 2.
Conditions Studied
Interventions
- DRUG LY3962681
- OTHER Placebo (aCSF)
Study Locations (4)
Texas
- Austin Clinic PPD - Austin
Ehime
- Ehime University Hospital - Tōon
Oita Prefecture
- Oita University Hospital - Yufu
Tokyo
- P-One Clinic, Keikokai Medical Corporation - Hachiōji
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2024-08-27 |
| Est. Completion | 2029-05-05 |
| Phase | Phase 1 |
What NCT06565195 shows while recruiting
NCT06565195 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which LY3962681 is the first listed.
NCT06565195 reports a single indexed study location in Texas, Ehime, Oita Prefecture.
Frequently Asked Questions
What is clinical trial NCT06565195 about?
NCT06565195 is a clinical study titled "A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease". The purpose of this study is to evaluate the safety, tolerability, and PK/PD of LY3962681 in healthy volunteers and patients with Parkinson's disease. The study will be comprised of two parts, the Single Ascending Dose (SAD) study and the Multiple Ascending Doses (MAD) study. During the SAD portion...
What is the current status of trial NCT06565195?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2024-08-27. Estimated completion is 2029-05-05.
What conditions does trial NCT06565195 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT06565195?
The interventions under investigation include: LY3962681 (DRUG), Placebo (aCSF) (OTHER).
Who is sponsoring clinical trial NCT06565195?
This trial is sponsored by Prevail Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06565195 being conducted?
This trial has 4 study locations across Texas, Ehime, Oita Prefecture, Tokyo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06565195's enrollment target sits among peer trials
108 53rd of 158 higher than 106 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery
RECRUITING · Phase 1
-
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
RECRUITING · Phase 1
-
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
RECRUITING · Phase 1
-
Feasibility and Safety of autoloGous UncondItioneD pEripheral Nerve Tissue Delivery to the Substantia Nigra (GUIDE)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI